TOT BIOPHARM International Co. Ltd. (1875) AI Stock Analysis

• Market Cap: HK$1.68B
• Dividend Yield: N/A
• Average Volume (3M): 506.89K
• Price to Earnings (P/E): 211.4
• Beta (1Y): 0.56
• Revenue Growth: 9.41%
• EPS Growth: -32.69%
• Country: HK
• Employees: 611
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 772,787,900
• 10 Day Avg. Volume: 489,320
• 30 Day Avg. Volume: 506,886
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$3.00
• Price Target Upside: 35.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 71 Outperform
• Price Target: HK$3.00 ▲(35.14% Upside)

The overall stock score reflects strong financial recovery and favorable technical indicators, showing positive market momentum. However, the high valuation and liquidity concerns from negative Free Cash Flow present potential risks. The absence of dividend yield also limits its appeal for income investors.

TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model

Company Description

TOT BIOPHARM International Co. Ltd. (1875) is a leading biopharmaceutical company based in China, specializing in the research, development, manufacturing, and commercialization of oncology drugs and therapies. The company's core focus is on innovative biologics and biosimilars aimed at treating various forms of cancer. With a commitment to improving patient outcomes, TOT BIOPHARM leverages advanced technologies and strategic partnerships to deliver high-quality, affordable treatments.

How the Company Makes Money

TOT BIOPHARM generates revenue primarily through the sale of its oncology drugs and therapies. The company invests in the development of both proprietary biologics and biosimilars, which are critical in the treatment of cancer. Revenue streams include direct sales to healthcare providers and distributors, as well as potential licensing agreements and partnerships with other pharmaceutical companies for co-development and commercialization. Additionally, the company might receive government grants or subsidies that support its research and development efforts. Key factors contributing to its earnings include its robust pipeline of drug candidates, strategic collaborations, and its ability to bring cost-effective treatments to market.

TOT BIOPHARM International Co. Ltd. Financial Statement Overview

Summary

The company has shown significant improvement in revenue, profitability, and operational efficiency, with positive EBIT and EBITDA margins. The balance sheet is strong with low Debt-to-Equity Ratio and positive Return on Equity. However, liquidity remains a concern due to negative Free Cash Flow.

Income Statement

The company has shown a significant improvement in revenue and profitability. Gross Profit Margin and Net Profit Margin have improved substantially from negative to positive, indicating a turnaround. The EBIT and EBITDA margins have moved from negative to positive, highlighting improved operational efficiency. However, the company faced challenges in previous years with negative growth, which could indicate potential volatility.

Balance Sheet

The balance sheet is strong with a relatively low Debt-to-Equity Ratio, indicating prudent financial leverage. The Return on Equity has turned positive, suggesting effective use of shareholder funds. The Equity Ratio is stable, showing a solid equity base. The company has maintained a healthy cash position over the years, enhancing financial stability.

Cash Flow

The cash flow statements show some concerns. The Free Cash Flow remains negative, impacting the cash flow score. However, the company has improved its Operating Cash Flow to Net Income Ratio, reflecting better cash generation from operations. Continued negative Free Cash Flow indicates potential liquidity challenges, although the company has managed its financing activities to maintain cash reserves.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.10B	780.63M	442.18M	76.33M	22.49M
Gross Profit	782.43M	573.99M	370.62M	27.47M	15.53M
EBITDA	84.96M	10.45M	-5.41M	-224.51M	-254.71M
Net Income	34.76M	-37.76M	-49.92M	-261.22M	-288.50M
Balance Sheet
Total Assets	1.51B	1.43B	1.26B	710.26M	641.18M
Cash, Cash Equivalents and Short-Term Investments	381.26M	358.36M	458.05M	152.81M	225.53M
Total Debt	395.47M	345.65M	289.53M	208.56M	7.41M
Total Liabilities	779.12M	739.41M	546.59M	375.17M	58.83M
Stockholders Equity	729.65M	686.69M	713.88M	335.09M	582.36M
Cash Flow
Free Cash Flow	-7.17M	-146.77M	-180.19M	-290.45M	-285.30M
Operating Cash Flow	116.40M	56.43M	59.93M	-175.14M	-263.12M
Investing Cash Flow	-122.50M	-164.10M	-282.76M	-108.39M	12.53M
Financing Cash Flow	34.18M	38.23M	481.24M	212.08M	-61.71M

TOT BIOPHARM International Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Neutral. The current price of 2.22 is below the 20-day moving average (MA) of 2.41, above the 50-day MA of 2.17, and above the 200-day MA of 1.93, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 44.67 is Neutral, neither overbought nor oversold. The STOCH value of 12.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1875.

TOT BIOPHARM International Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	71 Outperform	HK$1.68B	211.43	0.99%	―	9.41%	-32.69%
6622	57 Neutral	HK$2.12B	―	-12.04%	―	260.78%	40.04%
2181	56 Neutral	HK$3.18B	―	-86.56%	―	190.48%	40.11%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
6978	37 Underperform	HK$2.75B	―	-228.99%	―	―	27.90%
2511	36 Underperform	HK$1.94B	―	-67.27%	―	―	47.42%
2185	32 Underperform	HK$3.71B	―	-14.87%	―	―	22.65%

TOT BIOPHARM International Co. Ltd. Corporate Events

BioDlink Reports Revenue Decline Amidst Global Expansion Efforts

BioDlink International Company Limited reported a 6% decrease in operating revenue for the first half of 2025, attributed to intensified competition and delayed project milestones. Despite a significant 87% drop in net profit, the company expanded its international presence with Bevacizumab injection approvals in Nigeria and Pakistan, and GMP inspections passed in several countries. The company also authorized Zhaoke Ophthalmology Limited as the marketing authorization holder for TAB014 in China, marking a strategic move in the ophthalmic drug market.

BioDlink International Schedules Board Meeting for Interim Results

BioDlink International Company Limited has announced that its board of directors will convene on August 12, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

BioDlink International Rebrands with New Name and Identity

BioDlink International Company Limited has officially changed its English name from TOT BIOPHARM International Company Limited, effective July 11, 2025, following shareholder approval. This change is accompanied by amendments to the Articles of Association, a new stock short name ‘BIODLINK-B’ effective July 30, 2025, a new website address, and a new company logo, reflecting the company’s rebranding efforts.

TOT BIOPHARM Updates Nomination Committee Terms to Enhance Governance

TOT BIOPHARM International Co. Ltd. has announced the approval and implementation of new Terms of Reference for its Nomination Committee, effective July 1, 2025. The committee is tasked with reviewing the board’s structure, identifying qualified director candidates, and ensuring board diversity and independence. This move is expected to enhance the company’s governance and align its board composition with its strategic goals, potentially impacting its market positioning and stakeholder confidence.

TOT BIOPHARM Passes Key Resolutions at AGM

TOT BIOPHARM International Co. Ltd. successfully passed all proposed resolutions at its Annual General Meeting held on June 20, 2025. These resolutions included the approval of financial statements, re-election of directors, and granting of mandates for share allotment and buyback, indicating strong shareholder support and strategic alignment for future corporate governance and operational strategies.

TOT BIOPHARM Announces 2025 AGM Details and Key Resolutions

TOT BIOPHARM International Co. Ltd. has announced the details of its upcoming annual general meeting, scheduled for June 20, 2025. The meeting will address several key resolutions, including the approval of the company’s financial statements for 2024, the re-election of board members, and the reappointment of PricewaterhouseCoopers as auditors. Additionally, the meeting will consider authorizing the board to manage the company’s share capital, which could impact the company’s financial strategy and shareholder value.

TOT BIOPHARM Proposes Name Change to BioDlink International

TOT BIOPHARM International Co. Ltd. has announced a proposal to change its English name to BioDlink International Company Limited, subject to shareholder and regulatory approval. This name change is intended to better align with the company’s business strategy and enhance its corporate image, without affecting current shareholders’ rights or the company’s operations.